All In Biotech

Drug Trial Radar · NCT05924815

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

A Randomized, 2-Part, Single-Dose, Crossover Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval in Healthy Participants

Last checked: Nov 20, 2026Latest source record: Dec 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

May 15, 2023

Primary completion

Nov 14, 2023

Study completion Nov 14, 2023

Sponsor

Lead sponsor
CytokineticsIndustry
Sponsor type
Industry
First posted
Jun 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A (Dose Finding) is an open-label, SAD study to identify the dose for Part B. Part B (TQT Study) is a randomized, double-blind (with respect to aficamten and matching placebo), positive- and placebo-controlled, single-dose, 3-way crossover study to evaluate the effect of aficamten administration on QT/QTc interval.

Conditions

  • Healthy Participants

Interventions

  • AficamtenDrug

    Oral Tablet

  • Aficamten-matching PlaceboDrug

    Oral Tablet

  • MoxifloxacinDrug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: To determine the dose for Part BTime frame: Baseline to End of Study, up to 8 weeks
  2. Part B: placebo-corrected dQTcF for aficamtenTime frame: Baseline to End of Study, up to 14.5 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion, Inc 2420

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.